Mer­ck­'s $10.8B Prometheus buy­out can pro­ceed af­ter an­titrust re­view

The gov­ern­ment’s wait­ing pe­ri­od for Mer­ck’s $10.8 bil­lion Prometheus Bio­sciences buy­out ex­pired on Mon­day, mean­ing the com­pa­nies can pro­ceed to close the deal, ac­cord­ing to an SEC fil­ing.

Prometheus an­nounced the merg­er last month af­ter field­ing in­ter­est from sev­er­al oth­er phar­ma com­pa­nies, in­clud­ing Ab­b­Vie and Bris­tol My­ers Squibb, ac­cord­ing to a Bloomberg re­port. It gives Mer­ck PRA023, an ex­per­i­men­tal an­ti-TL1A an­ti­body for in­flam­ma­to­ry bow­el dis­ease that Mer­ck ex­pects will play a big role in its fu­ture be­yond Keytru­da’s patent cliff.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN